Comparing [¹⁸F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.

ABSTRACT:

Background

The PHERGain trial demonstrated that an [¹⁸F]2-fluoro-2-deoxy-d-glucose ([¹⁸F]FDG)-positron emission tomography (PET)-based, pathological complete response (pCR)-adapted strategy could be safely utilized to avoid chemotherapy (CT) in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) receiving neoadjuvant dual anti-HER2 blockade [trastuzumab and pertuzumab (HP)]. Due to the limited availability of [¹⁸F]FDG-PET, this study evaluated breast magnetic resonance imaging (MRI) as an alternative for early treatment response assessment.

Patients and methods

Group B patients (n = 285) initially received two cycles of HP, with subsequent CT introduction if [¹⁸F]FDG-PET showed no respon

SUBMITTER: Garcia-Mosquera JJ 

PROVIDER: S-EPMC12639436 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature